You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

353 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Primary Advanced or Recurrent Endometrial Carcinoma
Sep 2025
Drug
Other Name(s): Vitrakvi®
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Drugs Used:
nivolumab (Compassionate),
ipilimumab (Compassionate)
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Drugs Used:
nivolumab (Compassionate),
ipilimumab (Compassionate)
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Curative
Sep 2025

Pages